Signage for Shiseido Co. is displayed outside the company's headquarters in Tokyo, Japan, on Friday, Feb. 28, 2014. Shiseido, Japan's largest cosmetics maker, is under reform after posting losses due to weak domestic sales and an impairment loss on goodwill associated with Bare Escentuals, which it bought in 2010. Photographer: Kiyoshi Ota/Bloomberg
But, there’s an even more important step to take – your participation and contribution. The topic of “a cure for hair loss” or “a hair growth treatment”, for many of us, is one of the most important issues in our lives. What are you doing to support its success? I realize that question may not have previously crossed the mind for many. It’s here now. For a personal example, I’m not a scientist who creates molecules in a lab, so I decided I would organize the hair growth treatment news and spread awareness. It’s been a gratifying practice for me.
Regarding the RCH news, is your source more reliable than Lee Buckler since he seems to know more about RCH than Lee buckler himself. Recently, Lee Buckler tweeted “We anticipate seeing data from the RCH-01 study in Japan sometime before year-end but the real answer is whenever the investigators/hospitals in charge of the trial (not us) decide to release the data once it ready”
This moisturizing double-duty product is incredibly well rated (and you don’t even have to pay the pink tax to boot). Soy proteins and shea butter add silky strength, while scalp-tingling peppermint and rosemary provide minty freshness and lift at the root. “The thickening properties of the shampoo are great at this price point, so if you have thin or thinning hair, this will add some volume,” wrote one reviewer. “I also noticed that this is the first shampoo/conditioner shampoo that tends to actually condition your hair."
Dupilumab is FDA approved for treating eczema aka atopic dermatitis and sold under the brand name Dupixent. As the story goes, a patient with alopecia totalis (a form of areata which leaves a person’s head completely bald) was being treated for eczema by the drug Dupixent. After 6 weeks the patient first began to notice progress in terms of hair growth and at 7 months she had noticeable pigmented hair growth on her scalp. Notably, the patient stopped taking the dupilumab for a period of time and noticed her growth subsided; when she began taking the drug again the hair improved once more. This provides another useful therapy option for patients seeking treatment for AA. One would imagine a topical version would be worthwhile to investigate.